Equities

SkinBioTherapeutics PLC

SBTX:LSE

SkinBioTherapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)10.15
  • Today's Change0.40 / 4.10%
  • Shares traded686.11k
  • 1 Year change-42.00%
  • Beta2.3127
Data delayed at least 20 minutes, as of May 17 2024 16:12 BST.
More ▼

Profile data is unavailable for this security.

About the company

SkinBioTherapeutics plc is a United Kingdom-based life science company, which is focused on skin health. The principal activity of the Company is that of research and development focused on harnessing the microbiome for human health. The Company’s segments include UK, US, and EU. The Company's platform technology, SkinBiotix, applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company is targeting five specific skin healthcare sectors, such as cosmetics skincare, food supplements for the treatment of skin conditions, medical skin care, infection control in both the home and the hospital environment, and pharmaceuticals for the prescribed treatment of skin conditions. The Company's product, AxisBiotix-Ps, is a food supplement to address the symptoms of mild to moderate psoriasis. The Company is also focused on the application of SkinBiotix technology in the treatment of various classes of skin wounds.

  • Revenue in GBP (TTM)161.65k
  • Net income in GBP-2.88m
  • Incorporated2015
  • Employees11.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SBTX:LSE since
announced		Transaction
value
Dermatonics LtdDeal completed25 Jan 202425 Jan 2024Deal completed-31.19%3.73m
Data delayed at least 20 minutes, as of May 17 2024 16:12 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Proteome Sciences plc5.03m-2.44m11.51m35.0011.51m35.00
Chill Brands Group PLC146.62k-3.64m12.40m2.0012.40m2.00
Provexis plc598.08k-496.59k13.58m2.0013.58m2.00
Abingdon Health PLC5.34m-2.24m13.62m82.0013.62m82.00
Shield Therapeutics PLC13.09m-33.29m13.69m73.0013.69m73.00
Synairgen plc0.00-9.99m14.10m30.0014.10m30.00
Destiny Pharma PLC0.00-5.66m15.01m19.0015.01m19.00
Genincode PLC1.72m-6.73m15.48m28.0015.48m28.00
LungLife AI Inc36.22k-4.26m15.75m15.0015.75m15.00
OptiBiotix Health PLC689.10k-13.17m17.75m3.0017.75m3.00
Oncimmune Holdings PLC1.15m-6.15m18.16m56.0018.16m56.00
Incanthera PLC0.00-1.48m18.86m8.0018.86m8.00
Verici DX PLC14.96k-8.83m19.96m14.0019.96m14.00
Hemogenyx Pharmaceuticals PLC0.00-6.69m20.33m17.0020.33m17.00
Skinbiotherapeutics PLC161.65k-2.88m20.34m11.0020.34m11.00
Oxford Biodynamics PLC510.00k-10.83m24.29m45.0024.29m45.00
Data as of May 17 2024. Currency figures normalised to SkinBioTherapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

18.14%Per cent of shares held by top holders
HolderShares% Held
Yarra Investment Management Ltd.as of 30 Nov 202313.82m6.90%
Odd Asset Management Ltd.as of 05 Jan 202313.17m6.57%
Unicorn Asset Management Ltd.as of 08 Apr 20247.89m3.94%
Evelyn Partners Investment Management LLPas of 31 Dec 20231.46m0.73%
More ▼
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.